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Abstract
Placental development is important for proper in utero growth and development of 
the fetus, as well as maternal well-being during pregnancy. Abnormal differentiation 
of placental epithelial cells, called trophoblast, is at the root of multiple pregnancy 
complications, including miscarriage, the maternal hypertensive disorder preeclampsia 
and intrauterine growth restriction. The ligand-activated nuclear receptor, PPARγ, and 
nutrient sensor, Sirtuin-1, both play a role in numerous pathways important to cell 
survival and differentiation, metabolism and inflammation. However, each has also been 
identified as a key player in trophoblast differentiation and placental development. This 
review details these studies, and also describes how various stressors, including hypoxia 
and inflammation, alter the expression or activity of PPARγ and Sirtuin-1, thereby 
contributing to placenta-based pregnancy complications.
Introduction
Placental development
The placenta is a unique organ present only during 
intrauterine life, but contributing significantly to fetal 
growth and development (Burton & Jauniaux 2015). It 
comprises epithelial cells derived from the trophectoderm 
(TE), the outer layer of blastocyst and of extraembryonic 
mesodermal (ExM) cells derived from the inner cell mass 
(ICM), the cells which give rise to the embryo-proper 
(James et al. 2012). Over time, this combination of cells 
gives rise to an intricate organ, one that not only anchors 
the fetus within the uterine cavity, but also functions to 
provide the needed oxygen, nutrients and hormones for 
fetal growth and expel carbon dioxide and other waste. 
While the ExM gives rise to the mesenchymal portions 
of the placenta, including the fetal vasculature, the 
TE differentiates into two major trophoblast subtypes: 
villous trophoblast (labyrinthine trophoblast in mouse), 
involved in gas and nutrient exchange, and extravillous 
trophoblast (junctional zone in mouse), which anchor 
the placenta into the uterine wall and remodel maternal 
spiral arterioles in order to provide blood flow to the 
feto-placental unit (Fig.  1) (reviewed in Soncin et  al. 
2015). Abnormal development and/or function of this 
organ has significant consequences for both mother and 
baby, leading to complications ranging from gestational 
hypertension/preeclampsia and fetal growth restriction, 
gestational diabetes and macrosomia, to preterm delivery 
and stillbirth (Fisher 2015). In addition, more recent studies 
have shown that pregnancy complications, particularly 
those leading to aberrations in fetal growth, have a long-
term effect, contributing to metabolic programming of the 
offspring and thus increasing the risk of obesity, diabetes 
and cardiovascular disease, later in life (Thornburg & 
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Marshall 2015). This knowledge necessitates a deeper 
understanding of placental development, particularly 
pathways that can affect fetal growth. This review focuses 
on signaling pathways downstream of the nuclear receptor, 
PPARγ and the protein deacetylase, Sirt1, and how these 
pathways, individually and in combination, affect both 
the development and the function of the placenta.
PPARγ and Sirtuin-1
Peroxisome proliferator-activated receptor-γ (PPARγ) 
is a member of the family of ligand-activated nuclear 
hormone receptors, and a transcription factor known 
for its key role in glucose and lipid metabolism and 
adipocyte differentiation. Following dimerization with 
retinoid-X receptors (RXRs), PPARγ binds to specific DNA 
sequences termed PPARγ-responsive elements (PPREs) and 
induces genes involved in fatty acid uptake and storage, 
leading to lipid accumulation and adipogenesis. In fact, 
PPARγ is required for the formation of both white and 
brown adipose tissues, the former a site of energy storage 
and an endocrine organ, and the latter a site of energy 
expenditure and heat generation. PPARγ can be targeted 
using thiazolidinediones (TZDs), a family of synthetic 
agonists, which are most commonly used in treatment of 
type 2 diabetes (reviewed in Park et al. 2008, Koppen & 
Kalkhoven 2010).
Sirtuin-1 (Sirt1) is a member of the NAD+-dependent 
family of protein deacetylases and a nutrient sensor. 
Originally discovered in the budding yeast, Saccharomyces 
cerevisiae, as a gene able to regulate longevity, Sirt1 was 
first identified as a histone deacetylase, promoting 
chromatin compaction and hence silencing the 
genome in times of nutrient deprivation (reviewed in 
Giblin et  al. 2014). Since then, studies in mammalian 
systems have identified numerous non-histone targets 
of this deacetylase, including p53, FOXO1 and PPARγ. 
Notably, Sirt1 induction leads to PPARγ repression, 
thus inhibiting adipogenesis and enhancing fat 
mobilization, with the reverse phenotype shown by 
RNAi-induced Sirt1 downregulation (Picard et al. 2004). 
In addition to metabolism, Sirt1 has been found to 
influence numerous other pathways, including those 
involved in cell proliferation, apoptosis, autophagy 
and inflammation (reviewed in Knight & Milner 
2012, Simmons et  al. 2015). Sirt1 can be targeted by 
the naturally occurring compound, resveratrol, which 
has been identified as an anti-inflammatory agent and 
anti-oxidant, as well as by synthetic small molecules 
(Farghali et al. 2013).
While the negative regulation of PPARγ by Sirt1 has 
been the most well studied, the relationship between 
these two proteins is by no means simple. A recent study 
has shown that Sirt1-mediated deacetylation of PPARγ 
leads to the recruitment of a co-activator, Prdm1, and 
selective activation of PPARγ to promote ‘browning’ 
of white fat (Qiang et  al. 2012). In addition, PPARγ can 
also be an upstream negative regulator of Sirt1, both by 
binding and inhibiting its deacetylase activity and by 
reducing its transcription (Han et al. 2010). Finally, both 
the TZD class of PPARγ agonists and the Sirt1 inducer 
resveratrol have off-target effects, with TZDs inducing 
transient Sirt1 overexpression (Wei et  al. 2010), and 
resveratrol identified to also bind nuclear receptors in the 
PPAR family, including PPARγ (Calleri et al. 2014). Thus, 
evaluation of cross-talk between pathways regulated 
by these two proteins warrants careful experimentation 
and interpretation of results, particularly when using the 
common agonists.
In this review, we will focus on the role of the Sirt1-
PPARγ axis in the placenta, with additional focus on 
trophoblast, the epithelial compartment of the placenta. 
We will begin by detailing the role of each protein during 
placental development, and to the extent known, in 
trophoblast differentiation. Next, we will discuss how these 
pathways are modulated in placental disease, particularly 
those associated with the stressors, hypoxia, oxidative 
stress, inflammation and hyperglycemia. Throughout, 
we will also address the cross-talk between these two 
pathways (when known), as well as the therapeutic 
potential of targeting these pathways in placenta-based 
complications of pregnancy.
PPARγ in trophoblast differentiation and 
placental development
The gene for this protein is located on mouse chromosome 
6 and human chromosome 3; in both species, alternative 
splicing gives rise to multiple isoforms, but the most 
ubiquitous isoform and the one abundantly present 
in the placenta as well as in all trophoblast subtypes is 
PPARγ1 (Barak et al. 1999). Knockout of this gene in mice 
first revealed its importance in placental development: in 
its absence, embryos did not survive past midgestation 
(Barak et  al. 1999, Kubota et  al. 1999), and embryonic 
lethality could be rescued by either wild-type tetraploid 
aggregation (Barak et  al. 1999) or by generation of an 
epiblast-specific knockout, using Sox2-Cre mice (Duan 
et al. 2007), indicating that placental defects are the basis 
for the embryonic phenotype. In fact, PPARγ was expressed 
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in the placenta, beginning at embryonic day E8.0, prior 
to its expression in the embryo-proper (at E14.5) (Barak 
et  al. 1999). Evaluation of PPARγ-null placentae showed 
defects in labyrinth formation, with a thickened chorion 
persisting at E10.0, just after chorio-allantoic fusion 
should have taken place (Barak et al. 1999). To dissect out 
the role of PPARγ in the trophectoderm compartment, 
we derived trophoblast stem cells (TSC) from littermate 
wild-type (WT) and PPARγ-null blastocyst-stage (E3.5) 
mouse embryos (Parast et al. 2009). PPARγ-null TSCs grew 
slowly and showed altered differentiation in vitro, with a 
complete lack of labyrinthine trophoblast markers, instead 
showing significantly elevated markers of junctional zone 
(spongiotrophoblast and trophoblast giant cells/TGCs); in 
fact, functionally, differentiated PPARγ-null TSCs invaded 
Matrigel in greater numbers than differentiated WT-TSCs 
(Parast et  al. 2009). Reintroduction of the gene into 
PPARγ-null TSCs partially restored the differentiation 
phenotype, inducing the formation of syncytiotrophoblast 
and decreasing the number of cells able to invade Matrigel 
(Fig. 1A) (Parast et al. 2009).
The important role of PPARγ in trophoblast 
differentiation and placental development is also 
highlighted by studies using agonists. In vitro, treatment of 
mTSC with rosiglitazone shifted differentiation toward the 
labyrinthine lineage, and inhibited trophoblast invasion; 
these effects were absent in PPARγ-null TSCs, indicating 
they were PPARγ dependent (Parast et  al. 2009). Similar 
findings have been noted in human trophoblast, both 
primary extravillous trophoblast and the HIPEC65 cell 
line, with agonists inhibiting invasion in a concentration-
dependent manner (Fournier et  al. 2007). Interestingly, 
synthetic (troglitazone, a TZD), but not naturally 
occurring PPARγ agonists (15deltaPGJ2), enhanced 
differentiation of primary term cytotrophoblast (CTB) into 
syncytiotrophoblast (STB), both as assessed morphologically 
and by hCG secretion (Schaiff et al. 2000). Another TZD, 
rosiglitazone, was found to affect the secretory function of 
human trophoblast differentially, enhancing transcription 
of hCG alpha and beta subunits and hCG secretion in 
villous trophoblast but inhibiting the same in extravillous 
trophoblast (Handschuh et  al. 2009). Overall, these data 
suggest that the effects of PPARγ activation on trophoblast 
differentiation are similar between mouse and human, 
with enhancement of villous/labyrinthine trophoblast 
and inhibition of extravillous/junctional zone trophoblast, 
differentiation and function (Fig. 1A). The effects of PPARγ 
activation on placental development in vivo have also been 
evaluated, albeit to a lesser extent: continuous treatment 
with rosiglitazone between E10.5 and E18.5 led to a 
reduction in both the thickness of the spongiotrophoblast 
layer and in labyrinthine vasculature, resulting in smaller 
WT, but not PPARγ-heterozygous, embryos and placentas 
(Schaiff et al. 2007). In the same study, rosiglitazone also 
enhanced fatty acid accumulation in the placenta, but not 
in the embryo (Schaiff et al. 2007).
Limited data are available regarding PPARγ targets 
specific to the placenta and trophoblast. Perhaps the most 
well characterized is the mucin, Muc1, which localizes 
to the apical membrane of labyrinthine trophoblast, 
facing the maternal sinusoids (Shalom-Barak et  al. 
2004). Muc1 expression is lost in PPARγ-null placentas 
and induced following rosiglitazone treatment of WT 
mTSC (Shalom-Barak et  al. 2004). Muc1-null placentas 
show dilated maternal sinusoids with occasional blood 
Figure 1
Cartoon of trophoblast differentiation, indicating the role of PPARγ (A) 
or Sirt1 (B) expression and activation in the process. Terminology in 
parentheses refers to the mouse. Rosi, Rosiglitazone; Resv, Resveratrol. 
Arrow with circle at the end indicates an inhibitory effect on the 
indicated pathway.
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‘lakes,’ indicating that its expression is required for 
proper placental function (Shalom-Barak et  al. 2004). 
Our own study pointed to Gcm1, a master regulator of 
villous/labyrinthine trophoblast differentiation, as a 
gene downregulated in the absence of PPARγ (Parast et al. 
2009). A more recent study has provided evidence for 
Gcm1 as a potential direct target of PPARγ in the human 
choriocarcinoma cell line, BeWo, during induction of 
syncytialization (Levytska et  al. 2014). But perhaps the 
most thorough study of PPARγ targets in the placenta has 
been performed by Shalom-Barak et al. (2012), in which 
they used microarray-based RNA profiling to evaluate 
genes altered in both placentas and TSCs in the absence of 
PPARγ. Surprisingly, the vast majority of genes identified 
in this manner had not been identified as PPARγ targets in 
other organs; in addition, a significant proportion (40%) of 
the differentially expressed genes were similarly altered in 
RxRα-null placentas, confirming this protein to be a main 
PPARγ partner in the placenta (Shalom-Barak et al. 2012). 
Finally, since the bulk of the target genes were functionally 
linked to metabolism, rather than differentiation or 
development, the authors come to the thought-provoking 
conclusion that the severe phenotype of the PPARγ-null 
placenta indicates that proper trophoblast differentiation 
is tightly linked to metabolic function (Shalom-Barak 
et al. 2012).
Sirt1 in trophoblast differentiation and 
placental development
Similar to PPARγ, Sirt1 is ubiquitously expressed in both 
the mouse and human placenta (Chen et al. 2006, Lappas 
et al. 2011, (Arul Nambi Rajan et al. 2018). However, the 
phenotype of Sirt1-null embryos is more heterogeneous 
than PPARγ-null embryos, ranging from mid-to-late 
embryonic lethality to early postnatal lethality in inbred 
strains, depending on the genetic background of the mice 
(Cheng et  al. 2003, McBurney et  al. 2003, Wang et  al. 
2008). Nevertheless, a common phenotype among all 
strains appeared to be fetal growth restriction. Based on 
this observation, we obtained Sirt1-heterozygous mice on 
the Sv129 inbred background from Dr McBurney’s group, 
and set out to evaluate this embryonic phenotype in more 
detail (McBurney et  al. 2003). We observed embryonic 
lethality of Sirt1-null embryos at E13.5, confirmed their 
fetal growth restriction and observed that the placentas 
associated with these embryos were also small (Arul Nambi 
Rajan et al. 2018). Further histologic evaluation and in situ 
hybridization for various trophoblast markers revealed 
abnormalities in both the labyrinth and junctional zone. 
We therefore proceeded to derive WT and Sirt1-null TSC, 
again from littermate E3.5 embryos. In the absence of 
Sirt1, TSC grew slower, but the primary phenotype was 
that of blunted differentiation, with reduction of both 
labyrinthine and junctional zone markers (Arul Nambi 
Rajan et  al. 2018) (Fig.  1B). In fact, both in vitro and in 
vivo, Sirt1 deficiency led to an accumulation of an Epcam+ 
trophoblast progenitor population; this was accompanied 
by elevated levels of cMet, a receptor tyrosine kinase, 
which is required for the maintenance of this labyrinthine 
progenitor cell population (Ueno et  al. 2013). It is not 
immediately clear how Sirt1 deficiency leads to the 
persistence of cMet or whether this receptor is in fact a 
direct target of Sirt1’s deacetylase activity.
Notably, numerous other signaling pathways, some of 
which are known to be involved in TSC maintenance and 
differentiation, were also found to be altered in Sirt1-null 
TSC (Arul Nambi Rajan et  al. 2018). Among these were 
Smad- and Stat-dependent pathways, and also multiple 
metabolic pathways, including PPARγ. Interestingly, 
PPARγ RNA levels were reduced in differentiated 
Sirt1-null TSC, as confirmed by qPCR (Arul Nambi Rajan 
et al. 2018); this was somewhat unexpected, as Sirt1 is best 
known as a negative regulator of PPARγ in adipose tissue. 
However, PPARγ downregulation can also partly explain 
the blunted differentiation phenotype of Sirt1-null TSC, 
at least with respect to labyrinthine differentiation. As 
with PPARγ, we also evaluated the effect of Sirt1 agonists 
on TSC differentiation. Treatment with resveratrol during 
differentiation led to a Sirt1-dependent induction of 
the labyrinthine marker SynA, though inhibition of the 
spongiotrophoblast marker Tpbpa appeared to be Sirt1 
independent (Fig. 2). This agonist-induced shift towards 
a trophoblast lineage involved in nutrient exchange is 
consistent with the role of Sirt1 as a nutrient sensor and 
implies that Sirt1 may in fact serve a similar function in 
the placenta as in the embryo proper.
Sirt1 is also expressed in human trophoblast; 
however, to date, no published studies have addressed the 
role of this deacetylase in maintenance/differentiation 
of trophoblast in the human placenta. Similarly, while 
numerous Sirt1 targets have been identified, affecting 
pathways as wide-ranging as transcription, metabolism, 
apoptosis, DNA damage repair and autophagy (Simmons 
et  al. 2015), direct targets of Sirt1 in trophoblast and 
placenta are yet to be explored in detail. Our own 
study, using microarray-based RNA profiling of WT and 
Sirt1-null TSCs, before and after differentiation, identified 
a series of altered genes and pathways, some of which were 
mentioned earlier (Arul Nambi Rajan et  al. 2018), and 
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some of which overlapped with pathways regulated by 
Sirt1 outside the placenta. However, a detailed proteomic 
profiling study, particularly one focused on changes in 
acetylation is needed to identify potential direct targets 
of placental Sirt1.
Sirt1-PPARγ signaling in placental disease
Alterations in trophoblast differentiation and placental 
development are associated with numerous pregnancy 
complications, including miscarriage, pre-eclampsia, 
fetal growth restriction and gestational diabetes (Kwak-
Kim et  al. 2014, Fisher 2015, Huynh et  al. 2015). These 
conditions are associated with a suboptimal maternal 
and placental micro-environment, exhibiting features 
of hypoxia, oxidative stress, inflammation and/or 
hyperglycemia. Therefore, we will now attempt to 
summarize how these changes in micro-environment may 
affect PPARγ and/or Sirt1 signaling in the placenta. Since 
most studies regarding PPARγ and Sirt1 in trophoblast/
placenta have focused on hypoxia, we will begin with this 
topic.
Hypoxia and PPARγ
Oxygen tension is an important variable in the placenta, 
both during normal development and in specific diseases 
of this organ (reviewed in Chang et al. 2018). In conditions 
of low oxygen tension/hypoxia, numerous pathways are 
activated which subsequently affect tissue homeostasis. 
The best studied of these is that of hypoxia-inducible factor 
(HIF), a complex of two component proteins, the oxygen-
stabilized HIF-α and the constitutively expressed HIF-β 
subunits (Lee et  al. 2004). The HIF complex is required 
for placentation, and specifically for differentiation 
of trophoblast into the invasive lineage (trophoblast 
giant cells/TGCs in mouse and extravillous trophoblast 
in human) (Adelman et  al. 2000, Maltepe et  al. 2005, 
Wakeland et al. 2017). PPARγ was known to be affected by 
hypoxia through the HIF complex: specifically, adipocyte 
differentiation is inhibited by hypoxia, through a HIF-
regulated transcriptional repressor’s effect on PPARγ2, 
the isoform specific to adipose tissue (Yun et  al. 2002). 
Based on this study, we evaluated the effect of hypoxia 
on PPARγ in mouse TSCs. We found that low oxygen 
tension inhibits PPARγ expression, but that this effect is 
independent of HIF (Tache et al. 2013). In addition, forced 
expression of PPARγ under low oxygen tension partially 
restored labyrinthine trophoblast differentiation (Tache 
et al. 2013).
The above findings correlate with the hypoxia-
associated placental pathology present in the maternal 
hypertensive disorder of preeclampsia (PE). Abnormal 
differentiation of syncytiotrophoblast, the lineage 
analogous to labyrinthine trophoblast in mice, is a 
hallmark of this disease, and is considered secondary 
to the reduced maternal blood flow to the placenta due 
to abnormal spiral artery remodeling by the invasive 
extravillous trophoblast cells (Fisher 2015). In fact, PE 
placentas have reduced expression of PPARγ, as well as 
reduced levels of GCM1, a major regulator of labyrinthine/
syncytiotrophoblast formation and a potential target of 
Figure 2
The effect of resveratrol treatment on mouse trophoblast differentiation. 
Mouse TSCs were differentiated, as previously described (Arul Nambi 
Rajan et al. 2018), in the presence of 25 µM resveratrol or DMSO carrier 
for a total of seven days. qPCR was performed for markers of labyrinthine 
trophoblast (SynA, A) or junctional zone (Tpbpa, B); values were 
normalized to 18S RNA and shown as fold change adjusted to the value 
of wild-type (WT) undifferentiated (day 0) cells. Note that resveratrol 
induces SynA in a Sirt1-dependent manner (A); however, inhibition of 
Tpbpa expression is Sirt1-independent, as the basal levels in Sirt1-null 
cells are further decreased by resveratrol treatment in these cells (B). (A) 
*Indicates P value of 0.0007. (B) *Indicates P value of 0.0001 for WT and 
0.0057 for Sirt1-null cells.
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PPARγ, and its target the fusogenic protein, SYNCYTIN 
(Chen et al. 2004, Langbein et al. 2008, He et al. 2014). 
These PE-like syncytiotrophoblast abnormalities have 
been recapitulated in vitro by downregulation of GCM1 
in the floating human placental explant model (Baczyk 
et  al. 2009). We propose that this phenotype originates 
with downregulation of PPARγ under hypoxia, leading 
to reduced GCM1 and SYNCYTIN levels, which in turn 
adversely affect syncytiotrophoblast differentiation.
Another hallmark of PE is elevated circulating levels 
of the anti-angiogenic molecule soluble VEGF receptor-1, 
also known as soluble Flt-1 (sFlt-1) (Karumanchi & 
Epstein 2007). While the origin and etiology of elevated 
sFlt-1 secretion in PE placentas continue to be debated, 
several studies have shown a link between hypoxia and 
upregulation of sFlt-1 in human trophoblast (Nagamatsu 
et al. 2004, Li et al. 2005, Nevo et al. 2006, Munaut et al. 
2008). Our own study has shown a correlation between 
syncytiotrophoblast sFlt-1 levels and PE disease severity 
(Tache et  al. 2011). PPARγ activity has been linked to 
elevated levels of sFlt-1 in a rat model of PE: specifically, 
pregnant rats treated with a PPARγ antagonist exhibited 
PE-like symptoms such as elevated blood pressure, 
proteinuria and reduced pup weight, and accompanied 
by increased plasma levels of sFlt-1 (McCarthy et  al. 
2011). Interestingly, a separate study in mice linked 
reduced Gcm1 levels to elevated circulating levels of sFlt-1 
(Bainbridge et al. 2012). Together, these studies indicate 
that the PPARγ-Gcm1 axis may be involved in regulation 
of sFlt-1. We have also evaluated both sFlt-1 RNA levels 
and secretion in differentiated mouse TSC, following 
treatment with the PPARγ agonist rosiglitazone (Fig.  3). 
We noted reduced levels of sFlt-1 RNA and secretion 
following treatment with rosiglitazone; the latter did 
not affect sFlt-1 levels in WT-TSC subjected to hypoxia 
or in PPARγ-null TSC, under either normoxia or hypoxia, 
indicating that this effect was PPARγ dependent (Fig. 3).
Finally, PE is also characterized by increased levels of 
trophoblast apoptosis (Leung et al. 2001), a cellular process 
in which PPARγ is also involved. Interestingly, when term 
cytotrophoblast are cultured in hypoxia, differentiation 
into syncytiotrophoblast is blunted and under severe 
hypoxia, apoptosis results (Nelson et  al. 1999, Elchalal 
et  al. 2004). Treatment of these cells with the PPARγ 
agonist, troglitazone, under hypoxic conditions promoted 
differentiation and limited the apoptotic damage these 
cells experienced (Elchalal et al. 2004). Together, the data 
provided here suggest that PPARγ should be considered 
as an important therapeutic target in placental diseases 
such as PE.
Hypoxia and Sirt1
Compared to the PPARγ story, the relationship between 
hypoxia and Sirt1 is more complex. However, several 
studies have identified Sirt1 as an upstream regulator of 
HIF-α subunits. Sirt1 can deacetylate HIF-1α, thus blocking 
the recruitment of p300 and induction of HIF-regulated 
genes (Lim et  al. 2010); conversely, Sirt1 selectively 
stimulates HIF-2α activity, thus promoting signaling 
through this alternate HIF-α subunit during hypoxia 
(Dioum et  al. 2009). In turn, Sirt1 gene expression has 
been found to decrease in hypoxia, in a HIF-dependent 
manner, thus showing bi-directional signaling between 
these two pathways (Chen et  al. 2011). Expression of 
Sirt1 in trophoblast under hypoxic conditions is yet to 
be evaluated in detail. Our own studies using mouse TSC 
have not shown a consistent effect of hypoxia on Sirt1 
Figure 3
The effect of rosiglitazone treatment on sFlt-1 in mouse trophoblast. 
Differentiated mouse TSCs, either wild-type (WT) or PPARγ-null, were 
treated with 1 µM rosiglitazone or DMSO carrier, either in normoxia (21% 
oxygen, N) or hypoxia (2% oxygen, H), then subjected to either qPCR (A) 
or ELISA (B) for sFlt-1. (A) *Indicates P value of 0.0005. (B) *Indicates P 
value of 0.0002.
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expression (data not shown). However, one study, using 
human term primary trophoblast has shown induction of 
Sirt1 under hypoxia, leading to enhanced expression of 
the N-myc downregulated gene-1 (NDRG1) and reduced 
expression of p53, thus promoting cell survival (Chen 
et  al. 2006). Nevertheless, more detailed studies are 
required to determine the relationship between hypoxia, 
HIF and Sirt1 in both trophoblast and placenta.
Similar to PPARγ, Sirt1 levels have recently been found 
to be reduced in syncytiotrophoblast of PE placentas 
by quantitative immunohistochemistry (Broady et  al. 
2017). The authors hypothesize that, given Sirt1’s role in 
increasing longevity, this finding is likely associated with 
enhanced cellular senescence noted in PE (Broady et  al. 
2017). Sirt1 activity has also been linked to PE in several 
studies. In one study, the Sirt1 agonist, resveratrol, was 
shown to attenuate sFlt-1 secretion, which was induced 
following treatment of normal human placental explants 
with either cytokines (including TNFα) or hypoxia (1% 
oxygen); resveratrol was also able to reduce sFlt-1 secretion 
from explants from PE placentas, albeit by only 25–30% 
(Cudmore et al. 2012). In a more recent study, resveratrol 
was used to treat human primary term trophoblast, 
thereby reducing both secretion and mRNA levels of sFlt-1 
(Hannan et al. 2017). We recently used differentiated WT 
and Sirt1-null mouse TSC and showed that treatment 
with resveratrol did reduce sFlt-1 mRNA and secretion, 
in a Sirt1-dependent manner; unlike PPARγ, however, 
the absence of Sirt1 was associated with significantly 
lower basal levels of sFlt-1 (Fig. 4). Since PPARγ levels are 
decreased in the absence of Sirt1 (Arul Nambi Rajan et al. 
2018), there are likely one or more other targets through 
which Sirt1 mediates sFlt-1 basal levels. Finally, resveratrol 
was also able to reverse the elevated blood pressure and 
proteinuria in a rat model of PE, induced by treatment 
with NG-nitro-l-arginine methyl ester (l-NAME) (Zou 
et al. 2014). These data suggest that, while Sirt1 is required 
for the induction of basal sFlt-1 expression, it may also 
serve a viable therapeutic target for PE, similar to PPARγ.
Placental oxidative stress and the effects on  
PPARγ and Sirt1
PE placentas have also been associated with oxidative 
stress (Burton et al. 2009), a condition of excess reactive 
oxygen species (ROS), which can be secondary to 
hypoxia, ischemia/reoxygenation or decreased levels of 
antioxidants. Since the effects of hypoxia were discussed 
earlier, we will focus here on oxidative stress induced by 
means other than hypoxia. In a rat model of maternal 
micronutrient deficiency, diets lacking either folic acid or 
vitamin B12 during pregnancy led to increased plasma 
markers of oxidative stress and lower levels of placental 
PPARγ mRNA; however, while the placenta weights were 
not affected, no fetal or maternal consequences were 
described (Meher et al. 2014). With regard to Sirt1, oxidative 
stress, induced by hypoxanthine/xanthine oxidase 
treatment of human placental explants, decreased Sirt1 
mRNA and protein expression and reduced the expression 
of the glucose transporter gene, GLUT1, and subsequent 
glucose uptake (Lappas et al. 2012). The latter phenotypes 
were abrogated by treatment with resveratrol (Lappas et al. 
2012). Similarly, resveratrol treatment reduced placental 
oxidative stress and apoptosis in the above-described rat 
model of L-NAME-induced PE (Zou et  al. 2014). In our 
study of mouse TSC, microarray-based RNA profiling 
identified the glutathione peroxidase genes, Gpx1 and 
Figure 4
The effect of resveratrol treatment on sFlt-1 in mouse trophoblast. 
Differentiated mouse TSCs, either wild-type (WT) or Sirt1-null, were 
treated with 25 µM resveratrol or DMSO carrier, then subjected to either 
qPCR (A) or ELISA (B) for sFlt-1. (A) *Indicates P value of 0.0185. (B) 
*Indicates P value of 0.0243.
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Gpx3, in the top 10 genes downregulated in Sirt1-null 
TSCs (Fig. 5A). The Gpx family of proteins helps protect 
cells against oxidative stress by catalyzing the reduction 
of organic hydroperoxides and hydrogen peroxide by 
glutathione (Matsubara et  al. 2015). Downregulation of 
Gpx1 and Gpx3 in Sirt1-null TSC, compared to WT-TSC, 
was confirmed by qPCR and was associated with a higher 
rate of apoptosis in the Sirt1-null cells (Fig.  5B and C). 
Whether Sirt1-null TSCs are more susceptible to oxidative 
stress due to the significant reduction in Gpx enzymes 
remains to be further evaluated.
Placental inflammation and the effects on  
PPARγ and Sirt1
Inflammation in the placenta can be either physiologic 
or pathologic. An example of the former is the increased 
inflammation noted in the placenta and fetal membranes 
in normal term labor (reviewed in Hadley et  al. 2017). 
This pro-inflammatory environment at labor has been 
associated with no change in PPARγ (Marvin et al. 2000), 
but a reduction in Sirt1 expression in both fetal membranes 
(chorion) as well as placental (chorionic villous) tissues 
(Lappas et  al. 2011, Kim et  al. 2013). Human placental 
Sirt1 levels are sensitive to pro-inflammatory cytokines, 
and have been shown to decrease following treatment 
with TNF and IL1β (Lappas et  al. 2011). Intriguingly, 
visfatin/Nampt, an adipocytokine and Sirt1 activator, had 
a positive correlation with Sirt1 levels and was found to 
be elevated in placentas of obese women prior to term 
labor, suggesting a potential mechanism whereby the 
labor-associated decrease in Sirt1 is prevented, resulting in 
post-term delivery commonly observed in obese pregnant 
women (Tsai et al. 2015).
Pathologic inflammation in the placenta is associated 
with PE as well as maternal obesity (Harmon et al. 2016, 
Leon-Garcia et  al. 2016). Elevated levels of placental 
inflammation have been associated with reduced 
placental PPARγ mRNA expression, in the setting of 
micronutrient deficiency in pregnant rats (Meher et  al. 
2014). Interestingly, in a mouse model of LPS-induced 
intrauterine fetal demise (IUFD), pre-treatment of 
pregnant mice with the PPARγ agonist, rosiglitazone, 
reduced the rate of IUFD from 64% to 16% (Bo et  al. 
2016). This effect was associated with increased nuclear 
localization of PPARγ in placental trophoblast, reductions 
in placental pro-inflammatory factors including IL-6 and 
TNFα and blockage of LPS-evoked nuclear translocation 
of NF-κB in labyrinthine trophoblast (Bo et  al. 2016). 
Finally, in a rat model of LPS-induced PE, transplantation 
of human umbilical cord mesenchymal stem cells (MSCs) 
led to reduced pro-inflammatory markers, including IL-6 
and TNFα, and higher levels of PPARγ, in the placenta; 
this was accompanied by lower blood pressure and higher 
fetal weight, compared to LPS treatment alone (Wang 
et al. 2016).
Less is known about the relationship between obesity-
associated placental inflammation and Sirt1/PPARγ 
expression. This type of inflammation is characterized 
by infiltration of T cells and macrophages into chorionic 
villi, best described as a non-infectious chronic villitis/
villitis of unknown etiology; in the setting of maternal 
obesity, this lesion is twice as common in placentas from 
female fetuses, a phenomenon that remains unexplained 
(Leon-Garcia et al. 2016). While macrophage infiltration 
of adipose tissue has been associated with decreased 
Sirt1 expression (Gillum et al. 2011), we have not noted 
alterations in Sirt1 or PPARγ expression in placentas 
Figure 5
Reduced expression of glutathione peroxidase genes and elevated 
apoptotic index in Sirt1-null mouse TSCs. (A) Microarray profiling of 
wild-type (WT) or Sirt1-null TSCs revealed two glutathione peroxidase 
genes, Gpx1 and Gpx3, to be in the top 10 of genes downregulated in 
the absence of Sirt1. (B) qPCR confirmed these findings. *Indicates 
P = 0.0002 for Gpx1 and P = 0.0001 for Gpx3. (C) Double-labeling of WT 
and Sirt1-null TSCs with 7-AAD and annexin V showed doubling of 
apoptotic index (percent of annexin V+/7AAD− cells).
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associated with maternal obesity (data not shown). 
However, in a study using a mouse model of high-fat 
feeding during pregnancy, we noted reduced Sirt1 and 
increased PPARγ expression in placentas (Qiao et al. 2015). 
This was associated with elevated placental lipoprotein 
lipase (LPL) protein and activity, as well as increased fetal 
body fat content, suggesting that maternal overnutrition 
affects fetal development through alterations in the Sirt1-
PPARγ axis (Qiao et  al. 2015). Whether this phenotype 
works through inflammatory mediators remains to be 
seen. We have noted a reduction in Sirt1 levels in WT 
mouse TSCs treated with IL-6 (data not shown); however, 
we have not yet evaluated how this is linked to other 
markers of trophoblast differentiation or function.
Hyperglycemia and placental PPARγ and Sirt1
Finally, while there have not been any studies on 
alterations of placental Sirt1 in the setting of maternal 
diabetes, studies on placental PPARγ levels in this setting 
have shown noteworthy results. PPARγ levels were 
increased both in human primary trophoblast exposed 
to hyperglycemic conditions (Cawyer et  al. 2014), 
as well as in placentas from streptozotocin-induced 
diabetic pregnant mice (Suwaki et al. 2007). At the same 
time, multiple studies have identified reduced placental 
PPARγ expression, in the setting of gestational diabetes 
(Jawerbaum et  al. 2004, Holdsworth-Carson et  al. 2010, 
Knabl et  al. 2014, Capobianco et  al. 2016), with one of 
these studies showing decreased levels of this protein in 
both syncytiotrophoblast and extravillous trophoblast 
(Knabl et  al. 2014). Further studies are needed to more 
thoroughly evaluate the link between maternal diabetes 
and PPARγ levels in trophoblast and placenta, with 
consideration of both maternal glycemic control and 
associated fetal/neonatal growth outcomes.
Figure 6 summarizes the effects of various stressors on 
both PPARγ and Sirt1 levels in the placenta.
Conclusions and future directions
While much remains to be evaluated regarding the 
function of both PPARγ and Sirt1, and particularly of 
the latter, in the placenta, the above studies indicate 
that both of these proteins play key roles, not just in 
the development of this important transient organ, but 
in the various pathologies associated with pregnancy 
complications. One of the major gaps in knowledge in 
this area is the role of these two proteins in placental 
nutrient sensing and the associated effect on fetal growth. 
While the absence of expression of each of these genes is 
associated with fetal growth restriction, their exact role(s) 
in placental nutrient sensing remain(s) to be explored. 
Furthermore, in such follow-up studies, the crosstalk 
between these two pathways must also be considered. 
For example, while PPARγ levels are significantly reduced 
in the absence of Sirt1 in mouse TSCs, Sirt1 appears to 
negatively regulate PPARγ in the placenta, in the setting 
of maternal high fat feeding, much like its function in 
white adipose tissue. While these results may be related 
to differences in the system being probed (single cell 
type in vitro vs the intact tissue in vivo), future studies 
should evaluate changes in expression of one protein, 
even if the other protein is the sole target. This is most 
important in experiments with agonists: in this context, 
TSCs derived from embryos genetically deficient for one 
or the other protein are highly useful for testing off-
target effects. In addition, evaluation of the functions of 
these proteins should ideally be done alongside accurate 
measurements of their endogenous activities; this will 
require development of more optimized activity assays, 
which can be carried out both in vitro and in vivo. Finally, 
further identification and characterization of downstream 
targets of both placental PPARγ and Sirt1 are needed, 
including potential shared targets. Given the availability 
Figure 6
Flow chart indicating relationship between placental PPARγ (A) or Sirt1 
(B) and various stressors. (+) indicates induction and (−) indicates 
inhibition of expression/activity (‘?’ indicates insufficient data). *Note 
that while hyperglycemia has been shown to increase PPARγ levels, the 
latter appear to be decreased in the setting of gestational diabetes. See 
text for further details on this and other stressors affecting either 
protein.
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of drugs targeting these pathways, future studies have 
the potential to lead to development of therapeutics for 
multiple placenta-based pregnancy complications.
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